9.02

4.04% -0.38

After Hours: 9.15 0.13 +1.44%

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $9.02, with a volume of 491.89K. It is down -4.04% in the last 24 hours and up +26.33% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Previous Close:

$9.40

Open:

$9.6

24h Volume:

491.89K

Relative Volume:

0.59

Market Cap:

$204.42M

Revenue:

$146.07M

Net Income/Loss:

$-196.04M

P/E Ratio:

-0.5427

EPS:

-16.621

Net Cash Flow:

$-75.37M

1W Performance:

+0.22%

1M Performance:

+26.33%

6M Performance:

+41.60%

1Y Performance:

+103.15%

1-Day Range:

$8.90

$9.735

1-Week Range:

$8.90

$10.22

52-Week Range:

$3.6503

$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

228

Twitter

@Karyopharm

Next Earnings Date

2026-08-10

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	9.02	204.42M	146.07M	-196.04M	-75.37M	-16.62
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-26	Initiated	Rodman & Renshaw	Buy
Feb-05-26	Initiated	Cantor Fitzgerald	Overweight
Oct-13-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

Jun 18, 2026

Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell - Seeking Alpha

Jun 18, 2026

H.C. Wainwright reiterates Karyopharm stock rating on trial data By Investing.com - Investing.com Canada

Jun 18, 2026